Singapore: China's HUYA Bioscience has struck a partnership with Changzhou Center for Biotech Development (CZCBD) to focus on advancing the worldwide potential of innovations from bio-pharmaceutical companies located in Changzhou that could meet critical global pharmaceutical pipeline needs.

HUYA is focused on speeding the development and value creation for China sourced novel biopharmaceutical compounds in world-wide markets. HUYA has established a series of collaborations with leading universities and research institutes throughout China and has pioneered in-licensing of both preclinical and clinical stage compounds from the country.

The CZCBD, an institutional unit fully funded and supervised by the Changzhou Science and Technology Bureau, is the biotechnology development center to operate under local government supervision. It is dedicated to establishing a comprehensive bio-pharmaceutical innovation system and to transforming the output of the more than 800 biotechnology and pharmaceutical companies based within Changzhou.

This partnership enables HUYA and CZCBD to collaborate on promoting new drug development in China and worldwide. Local biopharmaceutical companies serviced by CZCBD will be able to leverage HUYA's global biopharmaceutical knowledge and network, and consult with HUYA's team of experts in drug development and commercialization. In turn, HUYA will have the right of priority review to evaluate certain research and development projects of local companies supported by CZCBD, providing advice and consultation as needed.

"HUYA is delighted to work with the prestigious Changzhou Center for Biotech Development in a partnership that aims to advance the development and commercialization of innovative pharmaceutical compounds and biomarkers," said Mr Clement Gingras, HUYA's Chief Technology Officer and Chief Operating Officer Asia. "We are very excited about this partnership and look forward to fruitful collaborations in the years to come."

Mr Xin Zhou, director, Changzhou Center for Biotech Development, expressed optimism about the collaboration. He said, "This partnership connects Changzhou's resources in biomedical science and technology with HUYA's experience and resources in international new drug development, broadens access to worldwide markets for Changzhou's biomedical companies, and accelerates the global reach of innovative pharmaceutical technologies and products from Changzhou."